The discovery of a novel TDP-43-dependent cryptic splicing event in a bona fide FTD–ALS risk gene opens up a multitude of new directions for validating UNC13A as a biomarker and therapeutic target in ALS and FTD. This evidence concerns the gene UNC13A and amyotrophic lateral sclerosis.